Cancer genomes are subject to diverse mutational processes that generate recognizable mutational signatures. Some processes are driven by defects in specific DNA repair pathways whereas others are characteristic of environmental mutagens.
CGP is next-generation sequencing (NGS) based assay that provides a comprehensive genomic profiling solution appropriate for formalin-fixed paraffin-embedded (FFPE) tissues from solid tumors. The assay detects multiple biomarkers associated with targeted and immune-therapies.
